Simulations Plus

SLP · NASDAQ

$18.50+$0.00 (+0.00%)TodayMarket closed · Oct 5, 7:30 PM ET

No price history for this range.

SLP analyst rating

HoldConsensus of 3 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold3
Underperform0
Sell0

12-month price target · 3 analysts

Average $17.59 (−4.9% downside)

Low: $16.16
Now: $18.50
High: $19.42

Upgrades and downgrades

The latest rating actions, newest first

SLP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
William Blair	Jun 17, 2026	Downgrade	Outperform → Market Perform	—	54%
TD Cowen	Apr 10, 2026	Maintains	Hold	$19.00 → $16.00	68%
TD Cowen	Jan 8, 2026	Maintains	Hold	$16.00 → $19.00	68%
BTIG	Dec 18, 2025	Downgrade	Buy → Neutral	—	46%

The case for and against

Updated Jan 5, 2026

Bull case

Simulations Plus Inc. has demonstrated strong organizational growth, with an impressive 30% increase in the total dollar value of awarded work not yet recognized in backlog in Q3 year-over-year. The company has also experienced notable improvements in proposal activity within the biotech sector, signaling increased confidence among clients as they navigate their budgeting cycles. Additionally, the software segment reported a substantial 22% year-over-year revenue increase, alongside a modest growth in services revenue, highlighting the company's robust position in the pharmaceutical research software market.

Bear case

Simulations Plus Inc reported a year-over-year revenue decline of 6% in F4Q:25, despite a full-year increase of 13%, indicating potential underlying weakness in its business model. The company's guidance for F1Q:26 anticipates further revenue decline of 3% to 5%, which raises concerns about its ability to maintain growth relative to competitors in the pharmaceutical technology sector. Additionally, the organic growth rate has been stagnant, with growth of only 5% in the first half of the fiscal year followed by declines of 3% and 6.5% in the latter quarters, signaling a troubling trend for the company's revenue trajectory.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.